{"id":92272,"date":"2025-11-07T12:05:02","date_gmt":"2025-11-07T11:05:02","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=92272"},"modified":"2025-11-07T12:25:38","modified_gmt":"2025-11-07T11:25:38","slug":"andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/","title":{"rendered":"Andera Partners\u2019 portfolio company Evommune successfully lists on New York Stock Exchange with a $150 million IPO"},"content":{"rendered":"<p style=\"font-weight: 400;\">Andera Partners today announced\u00a0that it participated in the $150 million IPO on NYSE of its portfolio company Evommune, demonstrating Andera\u2019s continued support of the company\u2019s value creation through clinical development and pipeline expansion. The Company is now trading under the ticker EVMN. The stock opened on October 16<sup>th<\/sup> at $17.25 in the company&rsquo;s public trading debut and closed at $20.23, up 26.4% from their $16.00 offering price.<\/p>\n<p style=\"font-weight: 400;\">The proceeds from the IPO will be used to fund the clinical development of its most advanced clinical-stage product candidate EVO756 (oral MRGPRX2 antagonist) in the Phase 2\/3 trials in chronic spontaneous urticaria (CSU) and atopical AD, as well as product candidate EVO301 in the Phase 2 trial of of AD. The remaining proceeds will support pipeline expansion on several early promising programs.<\/p>\n<p style=\"font-weight: 400;\"><strong>Y<\/strong><strong>uexin Yu<\/strong><strong>, <\/strong><strong>D<\/strong><strong>irector<\/strong><strong> at Andera Partners<\/strong>, added: <em>\u201cThe Evommune IPO is particularly remarkable given that 2025 has been a quiet biotech IPO year. This important transition allows the company to tap into the public market as it is fast advancing multiple Ph2 studies for EVO756 and EVO301. Evommune is clearly bringing something unique with its class leading oral MRGPRX2 antagonist starting in chronic urticaria and atopic dermatitis and with additional indications to come. Being its major investor since 2021, Andera Partners has accompanied the team led by Luis Pena through each development phase of the company and stays committed to its value creation trajectory.\u201d<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Andera Partners today announced\u00a0that it participated in the $150 million IPO on NYSE of its portfolio company Evommune, demonstrating Andera\u2019s continued support of the company\u2019s value creation through clinical development and pipeline expansion. The Company is now trading under the ticker EVMN. The stock opened on October 16th at $17.25 in the company&rsquo;s public trading&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-92272","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Andera Partners\u2019 portfolio company Evommune successfully lists on New York Stock Exchange with a $150 million IPO - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Andera Partners\u2019 portfolio company Evommune successfully lists on New York Stock Exchange with a $150 million IPO - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Andera Partners today announced\u00a0that it participated in the $150 million IPO on NYSE of its portfolio company Evommune, demonstrating Andera\u2019s continued support of the company\u2019s value creation through clinical development and pipeline expansion. The Company is now trading under the ticker EVMN. The stock opened on October 16th at $17.25 in the company&rsquo;s public trading...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-07T11:05:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T11:25:38+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Andera Partners\u2019 portfolio company Evommune successfully lists on New York Stock Exchange with a $150 million IPO\",\"datePublished\":\"2025-11-07T11:05:02+00:00\",\"dateModified\":\"2025-11-07T11:25:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/\"},\"wordCount\":247,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/\",\"name\":\"Andera Partners\u2019 portfolio company Evommune successfully lists on New York Stock Exchange with a $150 million IPO - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2025-11-07T11:05:02+00:00\",\"dateModified\":\"2025-11-07T11:25:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Andera Partners\u2019 portfolio company Evommune successfully lists on New York Stock Exchange with a $150 million IPO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Andera Partners\u2019 portfolio company Evommune successfully lists on New York Stock Exchange with a $150 million IPO - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/","og_locale":"fr_FR","og_type":"article","og_title":"Andera Partners\u2019 portfolio company Evommune successfully lists on New York Stock Exchange with a $150 million IPO - ANDERA PARTNERS","og_description":"Andera Partners today announced\u00a0that it participated in the $150 million IPO on NYSE of its portfolio company Evommune, demonstrating Andera\u2019s continued support of the company\u2019s value creation through clinical development and pipeline expansion. The Company is now trading under the ticker EVMN. The stock opened on October 16th at $17.25 in the company&rsquo;s public trading...","og_url":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2025-11-07T11:05:02+00:00","article_modified_time":"2025-11-07T11:25:38+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Andera Partners\u2019 portfolio company Evommune successfully lists on New York Stock Exchange with a $150 million IPO","datePublished":"2025-11-07T11:05:02+00:00","dateModified":"2025-11-07T11:25:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/"},"wordCount":247,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/","url":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/","name":"Andera Partners\u2019 portfolio company Evommune successfully lists on New York Stock Exchange with a $150 million IPO - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2025-11-07T11:05:02+00:00","dateModified":"2025-11-07T11:25:38+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-evommune-successfully-lists-on-new-york-stock-exchange-with-a-150-million-ipo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Andera Partners\u2019 portfolio company Evommune successfully lists on New York Stock Exchange with a $150 million IPO"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/92272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=92272"}],"version-history":[{"count":3,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/92272\/revisions"}],"predecessor-version":[{"id":92277,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/92272\/revisions\/92277"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=92272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=92272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}